J Huober1, S Gelber2, A Goldhirsch3, A S Coates4, G Viale5, C Öhlschlegel6, K N Price7, R D Gelber8, M M Regan9, B Thürlimann10. 1. Breast Center, Kantonsspital, St Gallen; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. Electronic address: jens.huober@med.uni-duesseldorf.de. 2. IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston; Frontier Science and Technology Research Foundation, Boston, USA. 3. Department of Medicine, European Institute of Oncology, Milan, Italy; Swiss Center for Breast Health, Sant'Anna Clinics, Lugano-Sorengo, Switzerland. 4. International Breast Cancer Study Group and Australian New Zealand Breast Cancer Trials Group, University of Sydney, Sydney, Australia. 5. Division of Pathology and Laboratory Medicine, IBCSG Central Pathology Office, European Institute of Oncology, University of Milan, Milan, Italy. 6. Department of Pathology, Kantonsspital, St Gallen, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. 7. Frontier Science and Technology Research Foundation, Boston, USA. 8. IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston; Frontier Science and Technology Research Foundation, Boston, USA; Department of Biostatistics, Harvard School of Public Health, Harvard Medical School. 9. IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston; Department of Biostatistics, Harvard School of Public Health, Harvard Medical School. 10. Breast Center, Kantonsspital, St Gallen; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland.
Abstract
BACKGROUND: To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. METHODS: Among 12,409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors. RESULTS: Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13-0.78, P = 0.01). CONCLUSION: Medullary tumors have a favorable prognosis compared with invasive ductal tumors.
BACKGROUND: To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. METHODS: Among 12,409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors. RESULTS: Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13-0.78, P = 0.01). CONCLUSION: Medullary tumors have a favorable prognosis compared with invasive ductal tumors.
Authors: P Karlsson; Z Sun; D Braun; K N Price; M Castiglione-Gertsch; M Rabaglio; R D Gelber; D Crivellari; J Collins; E Murray; K Zaman; M Colleoni; B A Gusterson; G Viale; M M Regan; A S Coates; A Goldhirsch Journal: Ann Oncol Date: 2011-02-16 Impact factor: 32.976
Authors: R Dendale; A Vincent-Salomon; E Mouret-Fourme; A Savignoni; J Medioni; F Campana; J R Vilcoq; A de la Rochefordière; T Soussi; B Asselain; P de Cremoux; A Fourquet Journal: Int J Biol Markers Date: 2003 Apr-Jun Impact factor: 2.659
Authors: Beat Thürlimann; Karen N Price; Richard D Gelber; Stig B Holmberg; Diana Crivellari; Marco Colleoni; John Collins; John F Forbes; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch Journal: Breast Cancer Res Treat Date: 2008-02-08 Impact factor: 4.872
Authors: Roberto A Leon-Ferre; Mei-Yin Polley; Heshan Liu; Judith A Gilbert; Victoria Cafourek; David W Hillman; Ahmed Elkhanany; Margaret Akinhanmi; Jenna Lilyquist; Abigail Thomas; Vivian Negron; Judy C Boughey; Minetta C Liu; James N Ingle; Krishna R Kalari; Fergus J Couch; Daniel W Visscher; Matthew P Goetz Journal: Breast Cancer Res Treat Date: 2017-09-14 Impact factor: 4.872
Authors: Inhye Park; Jiyoung Kim; Minkuk Kim; Soo Youn Bae; Se Kyung Lee; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam Journal: J Breast Cancer Date: 2013-12-31 Impact factor: 3.588
Authors: Jose Villacorta Hidalgo; Peter Bronsert; Marzenna Orlowska-Volk; Liliana B Díaz; Elmar Stickeler; Martin Werner; Annette Schmitt-Graeff; Gian Kayser; Miroslav Malkovsky; Paul Fisch Journal: Front Immunol Date: 2014-12-10 Impact factor: 7.561